Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: Basic aspects, clinical applications, and future prospects

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1119-1128

  Shimizu, Masahito ^a   Imai, Kenji ^a   Takai, Koji ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyclic retinoid; Chemoprevention; Clonal deletion; Combination therapy; HCC; Obesity; Phosphorylated RXRa

Indexed keywords

ACYCLIC RETINOID; BETA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; INTERFERON RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RETINOIC ACID; RETINOID DERIVATIVE; RETINOID X RECEPTOR ALPHA; RETINOL; RETINOL ESTER; STAT3 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIGAND BINDING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; ONCOGENE C FOS; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REVIEW;

EID: 84872573620     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803987940     Document Type: Review

References (76)

1. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996, 10, 940-954.
2. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev. 2006, 58, 712-725.
3. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58, 760-772.
4. Altucci, L.; Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer. 2001, 1, 181-193.
5. Altucci, L.; Leibowitz, M. D.; Ogilvie, K. M.; de Lera, A. R.; Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6, 793-810.
6. Muto, Y.; Moriwaki, H.; Ninomiya, M.; Adachi, S.; Saito, A.; Takasaki, K. T.; Tanaka, T.; Tsurumi, K.; Okuno, M.; Tomita, E.; Nakamura, T.; Kojima, T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 1996, 334, 1561-1567.
7. Muto, Y.; Moriwaki, H.; Saito, A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med. 1999, 340, 1046-1047.
8. Takai, K.; Okuno, M.; Yasuda, I.; Matsushima-Nishiwaki, R.; Uematsu, T.; Tsurumi, H.; Shiratori, Y.; Muto, Y.; Moriwaki, H. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology. 2005, 48, 39-45.
9. Okita, K.; Matsui, O.; Kumada, H.; Tanaka, K.; Kaneko, S.; Moriwaki, H.; Izumi, N.; Okusaka, T.; Ohashi, Y.; Makuuchi, M. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. J. Clin. Oncol. 2010, 28 Suppl 7s, 4024.
10. Shimizu, M.; Takai, K.; Moriwaki, H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci. 2009, 100, 369-374.
11. Shimizu, M.; Sakai, H.; Moriwaki, H. Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Front. Biosci. 2011, 16, 759-769.
12. Moriwaki, H.; Shimizu, M.; Okuno, M.; Nishiwaki-Matsushima, R. Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects. Hepatol. Res. 2007, 37(Suppl 2), S299-S302.
13. Matsushima-Nishiwaki, R.; Okuno, M.; Adachi, S.; Sano, T.; Akita, K.; Moriwaki, H.; Friedman, S. L.; Kojima, S. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 2001, 61, 7675-7682.
14. Matsushima-Nishiwaki, R.; Okuno, M.; Takano, Y.; Kojima, S.; Friedman, S. L.; Moriwaki, H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003, 24, 1353-1359.
15. Kanamori, T.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Tsurumi, H.; Kojima, S.; Moriwaki, H. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci. 2007, 98, 431-437.
16. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Yasuda, Y.; Tsurumi, H.; Moriwaki, H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009, 285, 210-217.
17. Shimizu, M.; Sakai, H.; Shirakami, Y.; Iwasa, J.; Yasuda, Y.; Kubota, M.; Takai, K.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-+(db)/+Lepr(db) mice. Cancer Prev. Res. 2011, 4, 128-136.
18. Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J. X.; Zhoa, L.; Gu, L. J.; Wang, Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72, 567-572.
19. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
20. El-Serag, H. B.; Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-2576.
21. Parikh, S.; Hyman, D. Hepatocellular cancer: a guide for the internist. Am. J. Med. 2007, 120, 194-202.
22. Kumada, T.; Nakano, S.; Takeda, I.; Sugiyama, K.; Osada, T.; Kiriyama, S.; Sone, Y.; Toyoda, H.; Shimada, S.; Takahashi, M.; Sassa, T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997, 25, 87-92.
23. Koda, M.; Murawaki, Y.; Mitsuda, A.; Ohyama, K.; Horie, Y.; Suou, T.; Kawasaki, H.; Ikawa, S. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000, 88, 529-537.
24. Tsukuma, H.; Hiyama, T.; Tanaka, S.; Nakao, M.; Yabuuchi, T.; Kitamura, T.; Nakanishi, K.; Fujimoto, I.; Inoue, A.; Yamazaki, H.; Kawashima, T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993, 328, 1797-1801.
25. Okada, S.; Shimada, K.; Yamamoto, J.; Takayama, T.; Kosuge, T.; Yamasaki, S.; Sakamoto, M.; Hirohashi, S. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994, 106, 1618-1624.
26. Sporn, M. B.; Newton, D. L. Chemoprevention of cancer with retinoids. Fed. Proc. 1979, 38, 2528-2534.
27. Muto, Y.; Moriwaki, H. Antitumor activity of vitamin A and its derivatives. J. Natl. Cancer Inst. 1984, 73, 1389-1393.
28. Alvarez, S.; Germain, P.; Alvarez, R.; Rodriguez-Barrios, F.; Gronemeyer, H.; de Lera, A. R. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int. J. Biochem. Cell Biol. 2007, 39, 1406-1415.
29. de The, H.; Marchio, A.; Tiollais, P.; Dejean, A. A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987, 330, 667-670.
30. Sever, C. E.; Locker, J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol. Carcinog. 1991, 4, 138-144.
31. Ando, N.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Expression of retinoid X receptor alpha is decreased in 3'-methyl-4-dimethylaminoazobenzeneinduced hepatocellular carcinoma in rats. Oncol. Rep. 2007, 18, 879-884.
32. Yan, T. D.; Wu, H.; Zhang, H. P.; Lu, N.; Ye, P.; Yu, F. H.; Zhou, H.; Li, W. G.; Cao, X.; Lin, Y. Y.; He, J. Y.; Gao, W. W.; Zhao, Y.; Xie, L.; Chen, J. B.; Zhang, X. K.; Zeng, J. Z. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 2010, 70, 2285-2295.
33. Matsushima-Nishiwaki, R.; Shidoji, Y.; Nishiwaki, S.; Yamada, T.; Moriwaki, H.; Muto, Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol. Cell Endocrinol. 1996, 121, 179-190.
34. Adachi, S.; Okuno, M.; Matsushima-Nishiwaki, R.; Takano, Y.; Kojima, S.; Friedman, S. L.; Moriwaki, H.; Okano, Y. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002, 35, 332-340.
35. Yoshimura, K.; Muto, Y.; Shimizu, M.; Matsushima-Nishiwaki, R.; Okuno, M.; Takano, Y.; Tsurumi, H.; Kojima, S.; Okano, Y.; Moriwaki, H. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci. 2007, 98, 1868-1874.
36. Solomon, C.; White, J. H.; Kremer, R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J. Clin. Invest. 1999, 103, 1729-1735.
37. Lee, H. Y.; Suh, Y. A.; Robinson, M. J.; Clifford, J. L.; Hong, W. K.; Woodgett, J. R.; Cobb, M. H.; Mangelsdorf, D. J.; Kurie, J. M. Stress pathway activation induces phosphorylation of retinoid X receptor. J. Biol. Chem. 2000, 275, 32193-32199.
38. Macoritto, M.; Nguyen-Yamamoto, L.; Huang, D. C.; Samuel, S.; Yang, X. F.; Wang, T. T.; White, J. H.; Kremer, R. Phosphorylation of the human retinoid X receptor alpha at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. J. Biol. Chem. 2008, 283, 4943-4956.
39. Yamazaki, K.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Kanemura, N.; Araki, H.; Tsurumi, H.; Kojima, S.; Weinstein, I. B.; Moriwaki, H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cellsphosphorylated RXR alpha is a critical target for colon cancer management. Gut. 2007, 56, 1557-1563.
40. Kanemura, N.; Tsurumi, H.; Okuno, M.; Matsushima-Nishiwaki, R.; Shimizu, M.; Moriwaki, H. Retinoid X receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk. Res. 2008, 32, 884-892.
41. Shankaranarayanan, P.; Rossin, A.; Khanwalkar, H.; Alvarez, S.; Alvarez, R.; Jacobson, A.; Nebbioso, A.; de Lera, A. R.; Altucci, L.; Gronemeyer, H. Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell. 2009, 16, 220-231.
42. Yamada, Y.; Shidoji, Y.; Fukutomi, Y.; Ishikawa, T.; Kaneko, T.; Nakagama, H.; Imawari, M.; Moriwaki, H.; Muto, Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol. Carcinog. 1994, 10, 151-158.
43. Araki, H.; Shidoji, Y.; Yamada, Y.; Moriwaki, H.; Muto, Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem. Biophys. Res. Commun. 1995, 209, 66-72.
44. Fukutomi, Y.; Omori, M.; Muto, Y.; Ninomiya, M.; Okuno, M.; Moriwaki, H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn. J. Cancer Res. 1990, 81, 1281-1285.
45. Nakamura, N.; Shidoji, Y.; Yamada, Y.; Hatakeyama, H.; Moriwaki, H.; Muto, Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem. Biophys. Res. Commun. 1995, 207, 382-388.
46. Nakamura, N.; Shidoji, Y.; Moriwaki, H.; Muto, Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem. Biophys. Res. Commun. 1996, 219, 100-104.
47. Yasuda, I.; Shiratori, Y.; Adachi, S.; Obora, A.; Takemura, M.; Okuno, M.; Shidoji, Y.; Seishima, M.; Muto, Y.; Moriwaki, H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol. 2002, 36, 660-671.
48. Obora, A.; Shiratori, Y.; Okuno, M.; Adachi, S.; Takano, Y.; Matsushima-Nishiwaki, R.; Yasuda, I.; Yamada, Y.; Akita, K.; Sano, T.; Shimada, J.; Kojima, S.; Okano, Y.; Friedman, S. L.; Moriwaki, H. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002, 36, 1115-1124.
49. Suzui, M.; Masuda, M.; Lim, J. T.; Albanese, C.; Pestell, R. G.; Weinstein, I. B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res. 2002, 62, 3997-4006.
50. Shimizu, M.; Suzui, M.; Deguchi, A.; Lim, J. T.; Xiao, D.; Hayes, J. H.; Papadopoulos, K. P.; Weinstein, I. B. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin. Cancer Res. 2004, 10, 6710-6721.
51. Suzui, M.; Shimizu, M.; Masuda, M.; Lim, J. T.; Yoshimi, N.; Weinstein, I. B. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol. Cancer Ther. 2004, 3, 309-316.
52. Tatsukawa, H.; Sano, T.; Fukaya, Y.; Ishibashi, N.; Watanabe, M.; Okuno, M.; Moriwaki, H.; Kojima, S. Dual induction of caspase 3-and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol. Cancer 2011, 10, 4.
53. Moriwaki, H.; Muto, Y.; Ninomiya, M.; Kawai, K.; Suzuki, Y.; Seto, T. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3'-methyl-N, N-dimethyl-4-aminoazobenzene. Gastroenterol. Jpn. 1988, 23, 546-552.
54. Kagawa, M.; Sano, T.; Ishibashi, N.; Hashimoto, M.; Okuno, M.; Moriwaki, H.; Suzuki, R.; Kohno, H.; Tanaka, T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 2004, 25, 979-985.
55. Sano, T.; Kagawa, M.; Okuno, M.; Ishibashi, N.; Hashimoto, M.; Yamamoto, M.; Suzuki, R.; Kohno, H.; Matsushima-Nishiwaki, R.; Takano, Y.; Tsurumi, H.; Kojima, S.; Friedman, S. L.; Moriwaki, H.; Tanaka, T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGFalpha-expressing oval-like cells and activated hepatic stellate cells. Nutr. Cancer 2005, 51, 197-206.
56. Komi, Y.; Sogabe, Y.; Ishibashi, N.; Sato, Y.; Moriwaki, H.; Shimokado, K.; Kojima, S. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab. Invest. 2010, 90, 52-60.
57. Sakabe, T.; Tsuchiya, H.; Endo, M.; Tomita, A.; Ishii, K.; Gonda, K.; Murai, R.; Takubo, K.; Hoshikawa, Y.; Kurimasa, A.; Ishibashi, N.; Yanagida, S.; Shiota, G. An antioxidant effect by acyclic retinoid suppresses liver tumor in mice. Biochem. Pharmacol. 2007, 73, 1405-1411.
58. Shimizu, M.; Suzui, M.; Deguchi, A.; Lim, J. T.; Weinstein, I. B. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin. Cancer Res. 2004, 10, 1130-1140.
59. Shao, R. X.; Otsuka, M.; Kato, N.; Taniguchi, H.; Hoshida, Y.; Moriyama, M.; Kawabe, T.; Omata, M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005, 128, 86-95.
60. Llovet, J. M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48, 1312-1327.
61. Tanaka, S.; Arii, S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009, 100, 1-8.
62. Nakagawa, T.; Shimizu, M.; Shirakami, Y.; Tatebe, H.; Yasuda, I.; Tsurumi, H.; Moriwaki, H. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett. 2009, 273, 250-256.
63. Moriwaki, H.; Yasuda, I.; Shiratori, Y.; Uematsu, T.; Okuno, M.; Muto, Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin. Cancer Res. 1997, 3, 727-731.
64. Ikeda, K.; Arase, Y.; Saitoh, S.; Kobayashi, M.; Suzuki, Y.; Suzuki, F.; Tsubota, A.; Chayama, K.; Murashima, N.; Kumada, H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32, 228-232.
65. Kubo, S.; Nishiguchi, S.; Hirohashi, K.; Tanaka, H.; Shuto, T.; Yamazaki, O.; Shiomi, S.; Tamori, A.; Oka, H.; Igawa, S.; Kuroki, T.; Kinoshita, H. Effects of long-term postoperative interferonalpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 2001, 134, 963-967.
66. Habu, D.; Shiomi, S.; Tamori, A.; Takeda, T.; Tanaka, T.; Kubo, S.; Nishiguchi, S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004, 292, 358-361.
67. Mizuta, T.; Ozaki, I.; Eguchi, Y.; Yasutake, T.; Kawazoe, S.; Fujimoto, K.; Yamamoto, K. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006, 106, 867-872.
68. Kitagawa, J.; Hara, T.; Tsurumi, H.; Ninomiya, S.; Ogawa, K.; Adachi, S.; Kanemura, N.; Kasahara, S.; Shimizu, M.; Moriwaki, H. Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K(2). J. Cancer Res. Clin. Oncol. 2011, 137, 779-787.
69. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Tsurumi, H.; Moriwaki, H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res. 2008, 14, 2806-2812.
70. Shimizu, M.; Moriwaki, H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment. PPAR Res. 2008, 2008, 181047.
71. El-Serag, H. B.; Tran, T.; Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126, 460-468.
72. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H.; Ohashi, Y. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res. 2006, 35, 204-214.
73. Siegel, A. B.; Zhu, A. X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115, 5651-5661.
74. Shimizu, M.; Kubota, M.; Tanaka, T.; Moriwaki, H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int. J. Mol. Sci. 2012, 13, 579-595.
75. Iwasa, J.; Shimizu, M.; Shiraki, M.; Shirakami, Y.; Sakai, H.; Terakura, Y.; Takai, K.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci. 2010, 101, 460-467.
76. Shimizu, M.; Sakai, H.; Shirakami, Y.; Yasuda, Y.; Kubota, M.; Terakura, D.; Baba, A.; Ohno, T.; Hara, Y.; Tanaka, T.; Moriwaki, H. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev. Res. 2011, 4, 396-403.